Sample records for cevre radyasyonu oelcuemleri

  1. General Plan-Based Environmental Impact Analysis Process Environmental Assessment, Altus Air Force Base (United States)


    arrive at their job site and in the early evening as workers depart for the day. This would typically coincide with the normal commuting patterns of...Surveillance Cameras . O&M 21 02-1059 Construct Turn Around at Main Gate. O&M 22 02-1086 Construct Kitchen in Dormitory, Building 213. O&M 23 02-1087 Repair...Carson, Lt Nadine, 97th CES/CEV Compton , MSgt Jeff, 97th AMW/SCBV Cooper, Dewey, 97th CE/CEVR Gaston, TSgt Jon, 97th CS/SCXP Hill, Sgt Mathew, 97th MDOS

  2. Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients. (United States)

    Bedimo, Roger; Kang, Minhee; Tebas, Pablo; Overton, Edgar T; Hollabaugh, Kimberly; McComsey, Grace; Bhattacharya, Debika; Evans, Christopher; Brown, Todd T; Taiwo, Babafemi


    HIV/hepatitis C virus (HCV) patients have a 3-fold increased fracture incidence compared to uninfected patients. The impact of HCV therapy on bone health is unclear. We evaluated bone turnover markers (BTM) in well-controlled (HIV RNA <50 copies/ml) HIV/HCV-coinfected patients who received pegylated interferon-α and ribavirin (PEG-IFN/RBV) in ACTG trial A5178. Early virologic responders (EVR: ≥2 log HCV RNA drop at week 12) continued PEG-IFN/RBV and non-EVRs were randomized to continuation of PEG-IFN alone or observation. We assessed changes in C-terminal telopeptide of type 1 collagen (CTX; bone resorption marker) and procollagen type I intact N-terminal propeptide (P1NP; bone formation marker), and whether BTM changes were associated with EVR, complete early virologic response (cEVR: HCV RNA <600 IU/ml at week 12), or PEG-IFN treatment. A total of 192 subjects were included. After 12 weeks of PEG-IFN/RBV, CTX and P1NP decreased: -120 pg/ml and -8.48 μg/liter, respectively (both p < 0.0001). CTX declines were greater in cEVR (N = 91; vs. non-cEVR (N = 101; p = 0.003). From week 12 to 24, CTX declines were sustained among EVR patients who continued PEG-IFN/RBV (p = 0.027 vs. non-EVR) and among non-EVR patients who continued PEG-IFN alone (p = 0.022 vs. Observation). Median decreases of P1NP in EVR vs. non-EVR were similar at weeks 12 and 24. PEG-IFN-based therapy for chronic HCV markedly reduces bone turnover. It is unclear whether this is a direct IFN effect or a result of HCV viral clearance, or whether they will result in improved bone mineral density. Further studies with IFN-free regimens should explore these questions.

  3. None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis.

    Directory of Open Access Journals (Sweden)

    Wen-Juei Jeng

    Full Text Available BACKGROUND & AIMS: A combination of pegylated interferon-alpha and ribavirin (PR is the standard therapy for patients with chronic hepatitis C. The impact of polymorphism of interleukin-28B (IL28B on sustained virological response (SVR to PR has been well documented in patients with CHC genotype-1 (GT1, but it is controversial in genotype-2 (GT2 CHC patients. This study investigated the predictability of six single nucleotide polymorphisms (SNP of IL28B on the treatment responses of PR in patients with CHC GT2. METHOD: 197 CHC GT2 consecutive patients who received PR treatment in our prospective cohort were enrolled. Hepatitis C virus (HCV genotyping, quantification of HCV-RNA and genotyping of the ten SNPs of IL28B were performed. Six SNPs of IL28B were chosen for analysis. The propensity score matching (PSM analysis was applied using patients with CHC GT1 in another prospective cohort as a positive comparison to avoid covariate bias. RESULTS: The distribution of the six SNPs was similar in GT1 and GT2 patients. Five of these SNPs had strong association with treatment responses in GT1 but not in GT2 patients. After PSM analysis, these five SNPs still showed strong association with rapid virological response (RVR, cEVR and SVR in GT1 and had no influence in GT2 patients. Furthermore, rs12979860 and baseline viral load were the predictors for both RVR and SVR in GT1 patients. However, only baseline viral load could predict RVR and SVR in GT2 patients. In addition, in patients without RVR, rs12979860 was the only predictor for SVR in GT1 but no predictor for SVR was found in GT2. CONCLUSIONS: The genetic polymorphisms of IL28B had no impact on treatment responses in GT2 patients.

  4. 慢性丙型肝炎个体化治疗方案的临床研究%Study of using an individualized treatment strategy to treat patients with chronic hepatitis C

    Institute of Scientific and Technical Information of China (English)

    南月敏; 郑欢伟; 孙殿兴; 安春绵; 李友生; 孔丽; 戴二黑; 张玉果; 赵素贤


    Objective To investigate the outcomes of chronic hepatitis C (CHC) patients treated with antiviral regimens of interferon (IFN) plus ribavirin (RBV) using individualized doses and durations.Methods This study was designed as an open-label,prospective clinical trial to analyze the virological responses of 169 CHC patients who received individualized dosages of IFNα-2b or pegylated (Peg)IFNα-2a combined with RBV based on their weight (< 60 kg or ≥ 60 kg),age (< 65 years or 65-75 years),morbid state (liver cirrhosis or not),and complications (such as heart disease,diabetes,thyroid disorder).Treatment duration was calculated using the time required to induce HCV RNA negativity.The rates of virological response and adverse effects among the different groups were compared.Results The IFNα-2b treatment was given to 116 patients,and PegIFNα-2a was given to 53 patients.Compared to the IFNα-2b group,the PegIFNα-2a group showed significantly higher rates of complete early virological response (cEVR; 76.7% vs.92.5%,P < 0.05) and sustained virological response (SVR; 53.6% vs.92.3%,P < 0.05) among the patients who had completed their course of treatment;the rapid virological response (RVR) rate was also higher for the PegIFNα-2a group but the difference did not reach statistical significance (48.7% vs.60.4%,P> 0.05).Seventy-eight patients received the routine dose,and 91 patients received the low dose; there were no significant differences between these two groups for RVR (53.8% vs.58.9%,P> 0.05),cEVR (78.0% vs.80.8%,P> 0.05),or SVR (65.5% vs.58.3%,P> 0.05).Conclusion Use of an individualized antiviral treatment strategy designed according to the patient's baseline condition,early viral kinetics,and tolerability to adverse reactions can achieve a high rate of SVR,as well as improve the safety,prognosis,and cost-effectiveness associated with treating CHC patients.%目的 探讨适于我国丙型肝炎病毒(HCV)慢性感染不